A Live Attenuated H7N3 Influenza Virus Vaccine is Well-tolerated and Immunogenic in a Phase I Trial in Healthy Adults

BACKGROUND: Live attenuated influenza vaccines (LAIV) are being developed and tested against a variety of influenza viruses with pandemic potential. We describe the results of an open label Phase I trial of a live attenuated H7N3 virus vaccine. METHODS AND FINDINGS: The H7N3 BC 2004/AA ca virus is a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Talaat, Kawsar R., Karron, Ruth A., Callahan, Karen A., Luke, Catherine J., DiLorenzo, Susan C., Chen, Grace L., Lamirande, Elaine W., Jin, Hong, Coelingh, Kathy L., Murphy, Brian R., Kemble, George, Subbarao, Kanta
Formato: Artigo
Idioma:Inglês
Publicado: 2009
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2771405/
https://ncbi.nlm.nih.gov/pubmed/19464558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2009.03.082
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares